Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma

被引：3
|
作者：
Ghatalia, Pooja [1 ]
Plimack, Elizabeth R. [1 ]
机构：
[1] Fox Chase Canc Ctr, Dept Hematol & Oncol, Philadelphia, PA 19111 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2023年 / 20卷 / 12期
关键词：
CISPLATIN; CHEMOTHERAPY; CANCER; UNFIT;
D O I：
10.1038/s41571-023-00814-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Following the recent FDA Accelerated Approval of enfortumab vedotin (EV) plus pembrolizumab for patients with advanced-stage urothelial carcinoma who are cisplatin-ineligible, herein we highlight key clinical outcomes with this combination based on results from Cohort K of the pivotal phase Ib/II EV-103 trial. We also discuss treatment sequencing, de-escalation strategies and toxicity management as EV-pembrolizumab becomes widely used in clinical practice.
引用
收藏
页码：818 / 819
页数：2
相关论文
共 50 条
  • [41] Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma A Population-Based Analysis
    Gockley, Allison A.
    Rauh-Hain, J. Alejandro
    Anders, Amber M.
    Meyer, Larissa A.
    Clemmer, Joel
    Lu, Karen H.
    Clark, Rachel M.
    Schorge, John O.
    del Carmen, Marcela G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (04) : 697 - 704
  • [42] Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
    Grivas, Petros
    Kopyltsov, Evgeny
    Su, Po-Jung
    Parnis, Francis X.
    Park, Se Hoon
    Yamamoto, Yoshiaki
    Fong, Peter C.
    Tournigand, Christophe
    Duran, Miguel A. Climent
    Bamias, Aristotelis
    Caserta, Claudia
    Chang, Jane
    Cislo, Paul
    di Pietro, Alessandra
    Wang, Jing
    Powles, Thomas
    EUROPEAN UROLOGY, 2023, 83 (04) : 320 - 328
  • [43] Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
    Tomita, Yoshihiko
    Yamamoto, Yoshiaki
    Tsuchiya, Norihiko
    Kanayama, Hiroomi
    Eto, Masatoshi
    Miyake, Hideaki
    Powles, Thomas
    Yoshida, Mizuki
    Koide, Yuichiro
    Umeyama, Yoshiko
    di Pietro, Alessandra
    Uemura, Hirotsugu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (02) : 383 - 395
  • [44] A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan
    Su, Po-Jung
    Xiao, Ying
    Lin, Amy Y.
    Goh, Connie
    Wu, Ethan
    Liu, Kevin
    Chou, Patrick
    Kuo, Kaitlin
    Palencia, Roberto
    Chang, Jane
    Kearney, Mairead
    Kapetanakis, Venediktos
    Benedict, Agnes
    CANCER REPORTS, 2023,
  • [45] Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis
    Lee, Jae-Lyun
    Desai, Chirag
    Park, Se Hoon
    Tsuchiya, Norihiko
    Su, Po-Jung
    Chan, Timothy Tim Wai
    Gurney, Howard
    Gao, Seasea
    Wang, Jing
    Sandner, Robin
    di Pietro, Alessandra
    Eto, Masatoshi
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 256.e17 - 256.e25
  • [46] Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
    Zhou, L.
    Yang, K. W.
    Zhang, S.
    Yan, X. Q.
    Li, S. M.
    Xu, H. Y.
    Li, J.
    Liu, Y. Q.
    Tang, B. X.
    Chi, Z. H.
    Si, L.
    Cui, C. L.
    Guo, H. Q.
    He, Z. S.
    Guo, J.
    Sheng, X.
    ANNALS OF ONCOLOGY, 2025, 36 (03) : 331 - 339
  • [47] Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma
    Miyake, Makito
    Shimizu, Takuto
    Nishimura, Nobutaka
    Kiba, Keisuke
    Maesaka, Fumisato
    Oda, Yuki
    Tachibana, Akira
    Tomizawa, Mitsuru
    Ohmori, Chihiro
    Matsumura, Yoshiaki
    Ichikawa, Kazuki
    Mizobuchi, Shinichiro
    Yoshikawa, Takanosuke
    Hori, Shunta
    Morizawa, Yosuke
    Gotoh, Daisuke
    Nakai, Yasushi
    Anai, Satoshi
    Torimoto, Kazumasa
    Aoki, Katsuya
    Tanaka, Nobumichi
    Fujimoto, Kiyohide
    CLINICAL GENITOURINARY CANCER, 2022, 20 (02) : 196.e1 - 196.e9
  • [48] Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale
    Miyake, Makito
    Nishimura, Nobutaka
    Oda, Yuki
    Miyamoto, Tatsuki
    Tomizawa, Mitsuru
    Shimizu, Takuto
    Hori, Shunta
    Morizawa, Yosuke
    Gotoh, Daisuke
    Nakai, Yasushi
    Torimoto, Kazumasa
    Fujii, Tomomi
    Tanaka, Nobumichi
    Fujimoto, Kiyohide
    JOURNAL OF CHEMOTHERAPY, 2025, 37 (02) : 146 - 158
  • [49] Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma
    Xie, Qian
    Zheng, Hanrui
    Chen, Ye
    Peng, Xingchen
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [50] Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
    Bellmunt, Joaquim
    Theodore, Christine
    Demkov, Tomasz
    Komyakov, Boris
    Sengelov, Lisa
    Daugaard, Gedske
    Caty, Armelle
    Carles, Joan
    Jagiello-Gruszfeld, Agnieszka
    Karyakin, Oleg
    Delgado, Francois-Michel
    Hurteloup, Patrick
    Morsli, Nassim
    Salhi, Yacine
    Culine, Stephane
    von der Maase, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4454 - 4461
12345